Dopamine

In the clinical rescue of acute and severe diseases such as shock and heart failure, the timely application of vasoactive drugs is directly related to the survival probability of patients. As a classic catecholamine drug, dopamine exerts a dose-dependent effect by agonizing α and β adrenergic receptors and peripheral dopamine receptors: low doses dilate renal blood vessels and increase renal blood flow, medium doses enhance myocardial contractility and increase cardiac output, and high doses constrict blood vessels and raise blood pressure. At present, it is widely used in the treatment of acute hypotension, myocardial infarction, renal failure, congestive heart failure and other diseases. It is a necessary rescue drug for emergency departments, ICUs and cardiovascular departments, and the applicable population covers acute and severe patients of all ages.

The global market size of dopamine preparations has been steadily maintained at more than 1.5 billion US dollars, with a compound annual growth rate of about 3.2%, among which the Chinese market accounts for more than 22%. As a classic drug that has been on the market for more than half a century, its market pattern is dominated by generic drugs. Nearly 30 domestic enterprises currently hold production approvals for dopamine injections. After the centralized procurement, the price of preparations has dropped by more than 80%, and the demand of downstream preparation enterprises for cost-effective and compliant APIs continues to rise. At present, the annual production capacity of domestic dopamine API exceeds 200 tons. In addition to meeting the needs of domestic preparation production, nearly 30% of the output is supplied to overseas markets.

The original research enterprise of dopamine is Abbott Laboratories of the United States, and the original research trade name is Intropin. Its core compound patent expired as early as 1985. The original research dosage forms are mainly injections, and the conventional specifications include 5ml:200mg, 10ml:200mg, etc. The original research product has been included in the FDA reference preparation catalog. At present, the original research preparation is not imported in China, and the reference preparation of domestic dopamine hydrochloride injection is the generic drug variety of domestic licensed enterprises. As of now, there are 19 registration entries of dopamine hydrochloride API on the CDE API registration platform, among which 14 have been publicized in Class A status and can be directly associated with preparation declaration. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for dopamine API, covering all categories such as process impurities and degradation impurities. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully meet the needs of API manufacturers in quality research, consistency evaluation and daily release testing.